April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Induction of vascular endothelial growth factor and vascular endothelial growth factor receptor after repeated bevicizumab treatment in human umbilical vein endothelial cells
Author Affiliations & Notes
  • Ji Eun E Lee
    Ophthalmology, Pusan National Univesity, Busan, Republic of Korea
    Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea
  • Hye Shin Jeon
    Ophthalmology, Pusan National Univesity, Busan, Republic of Korea
  • Jin Young Kim
    Ophthalmology, Pusan National Univesity, Busan, Republic of Korea
  • Jae Ho Jung
    Ophthalmology, Pusan National Univesity, Busan, Republic of Korea
    Convergent Biomedical Research Institute, Yangsan Pusan National University Hospital, Busan, Republic of Korea
  • Dong Hoon Shin
    Pathology, Pusan National Univesity, Busan, Republic of Korea
  • Min Kyu Shin
    Ophthalmology, Pusan National Univesity, Busan, Republic of Korea
  • Footnotes
    Commercial Relationships Ji Eun Lee, None; Hye Shin Jeon, None; Jin Young Kim, None; Jae Ho Jung, None; Dong Hoon Shin, None; Min Kyu Shin, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3452. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ji Eun E Lee, Hye Shin Jeon, Jin Young Kim, Jae Ho Jung, Dong Hoon Shin, Min Kyu Shin; Induction of vascular endothelial growth factor and vascular endothelial growth factor receptor after repeated bevicizumab treatment in human umbilical vein endothelial cells. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3452.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate expression of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in hypoxic human umbilical vein endothelial cells (HUVECs) after repeated anti-VEGF treatment.

Methods: HUVECs were incubated under the hypoxic environment with single or repeated treatment of bevacizumab at 1.0 or 2.5 mg/ml concentration. Treatment with identical volume of excipient was served as control. Expression of VEGF and phosphorylated VEGFR2 were assessed by enzyme-linked immuno-sorbant assay (ELISA) and western blot. Cytotoxicity and cell proliferation were also evaluated by MTT assay and immunocytochemistry of Ki-67.

Results: VEGF secretion was significantly higher after the single treatment than control and the repeated treatment groups (P < 0.05). VEGFR2 expression increased significantly after both a single and repeated bevacizumab treatments than control (P < 0.05). VEGFR2 expression was higher after repeated treatment than a single treatment, and in lower concentration of bevacizumab than higher concentration (P < 0.05). Cytotoxicity or inhibition of proliferation by bevacizumab was not observed.

Conclusions: A single treatment of anti-VEGF induced secretion of VEGF from HUVECs, whereas repeated treatments increased expression of VEGFR2. Elevated receptor expression may increase responsiveness to VEGF, and would be one of the mechanisms for losing efficacy of anti-VEGF treatment in vivo.

Keywords: 748 vascular endothelial growth factor • 548 hypoxia • 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×